Expect a dramatic finale to the Humira patent saga
Saturday Opinion: Alvotech’s speedy infringement trial could see its product jump the queue of adalimumab biosimilars in the final months before AbbVie’s exclusivity comes to an end
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.